Updated on 23 January 2015
Mr Joydeep Goswami, president-Life Sciences Solutions, Thermo Fisher Scientific, Asia Pacific and Japan
Singapore: "When looking in to the Asia Pacific and Japan's lifesciences industries trend in 2015 and beyond, the trend is towards the full-fledged use of the omics platforms and deeper search of the possibilities of synthetic biology, which will become more active.
To accelerate innovation driven by science, the region's ecosystem has been attracting global companies and entrepreneurs to place its important functions such as R&D, design, and manufacturing. This allows our region to lead the way in forming strategic partnerships between academia and industry to solve the biggest challenges facing humanity today.
Amid this environment, the demands for molecular biology platforms for genetics, genomics, proteomics, and metabolomics will rise, especially in the search to develop tools for comprehensive and early diagnosis, treatment stratification based on individual's genome and disease genetics, and regenerative medicine.
Highly innovative genetic analysis technologies are changing our approach to curing and managing complex diseases such as cancer, metabolic diseases such as diabetes, and infectious diseases such as TB. Faster, cheaper and more accurate, genetic analysis solutions, as exemplified by the semiconductor based next generation sequencing will have an expanded role to play in screening genetic profiles for drug candidate compounds or when enrolling patients into clinical trials for targeted therapy. Further, this technology will help to acquire genetic information that will become a strong support to clinicians when they are building treatment strategies for patients.
Another interesting trend that can be listed is the utilization of sequencing, qPCR, and mass spec technologies to better understand the microbiome and its influence on human health.
In the synthetic biology area, genome editing and genetic engineering technologies such as CRISPR and TALEN are rapidly opening new gateways to accelerate research in disease modeling, drug discovery and to evolve regenerative medicine.
The most interesting is that the above technologies not just deliver change to how we practice medicine. It is also has huge role for better animal health, crop and plant breeding; essential factor for sustainable food supply or in developing alternative energy resources. Simply these technologies promote the scientific community's efforts to make the world healthier, safer and cleaner.
Government sponsored R&D has consistently been one of the strongest contributors in creating the fundamental infrastructure of innovation in any economy. This innovation fuels job creation, exports, and in turn a stronger society. It also encourages further investment industry players that can take advantage of the basic science discoveries that government sponsored R&D yields. We would like policy makers in each of the economies to continue to invest in R&D.
Also, many of the cutting edge developments in diagnostics and healthcare welcome a new approach to regulatory frameworks, where closer partnership would help understand the new scientific discoveries and help bring them to the aid of patients faster. Currently, regulations in some countries are either non-existent or are based on principles that are not applicable to newer approaches to personalized medicine. Regulations reflecting the characteristics of the innovative health technologies need to be shaped so it can promote in delivering the benefits, while balancing between the demand for newer treatments to incurable diseases and the inevitable side-effect risk that any therapy poses."